Covered recipient · General Payments record
GISELLE S MOSNAIM
Allopathic & Osteopathic Physicians Allergy & Immunology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$94,781.58
103 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $43,102.00 | 17 |
| Consulting Fee | $37,493.00 | 17 |
| Travel and Lodging | $10,778.24 | 30 |
| Food and Beverage | $3,408.34 | 39 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $32,429.16 | 32 |
| AstraZeneca Pharmaceuticals LP | $22,656.53 | 31 |
| Novartis Pharmaceuticals Corporation | $13,923.92 | 9 |
| Genentech USA, Inc. | $13,384.67 | 9 |
| Chiesi USA, Inc. | $6,227.71 | 13 |
| Regeneron Pharmaceuticals, Inc. | $3,798.00 | 2 |
| Teva Pharmaceuticals USA, Inc. | $1,449.53 | 4 |
| ABBVIE INC. | $675.00 | 1 |
| Genentech, Inc. | $130.62 | 1 |
| GENZYME CORPORATION | $106.44 | 1 |
Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
GISELLE S MOSNAIM
NPI 1679501571 · CMS profile ID 1236302
Allopathic & Osteopathic Physicians / Allergy & Immunology
CHICAGO, IL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1679501571?year=2024&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- GISELLE S MOSNAIM, NPI 1679501571, CMS profile ID 1236302. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679501571?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). GISELLE S MOSNAIM, NPI 1679501571, CMS profile ID 1236302. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679501571?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- GISELLE S MOSNAIM, NPI 1679501571, CMS profile ID 1236302, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1679501571?year=2024&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
103 matching records · $94,781.58 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–103 of 103.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Genentech USA, Inc. | $0.98 | 02/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133015302 | CMS |
| Chiesi USA, Inc. | $53.17 | 02/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151814296 | CMS |
| Chiesi USA, Inc. | $623.29 | 02/15/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151814301 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $35,771.82 | 43 |
| PY2025 | Principal investigator | $909,194.22 | 238 |
| PY2024 | Recipient | $23,163.27 | 26 |
| PY2024 | Principal investigator | $414,530.15 | 204 |
| PY2023 | Recipient | $17,436.76 | 27 |
| PY2023 | Principal investigator | $294,538.05 | 51 |
| PY2022 | Recipient | $2,476.90 | 9 |
| PY2022 | Principal investigator | $162,081.35 | 19 |
| PY2021 | Principal investigator | $61,839.98 | 38 |
| PY2020 | Principal investigator | $12,250.00 | 2 |
| PY2019 | Principal investigator | $34,701.24 | 19 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
281 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 12/24/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133353 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 12/24/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133355 |
| Principal investigator 1 | GENZYME CORPORATION | $2,600.00 | 12/22/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226140652 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,804.96 | 12/17/2025 | Covered Recipient Teaching Hospital Skokie Hospital | A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately co | No dispute reported | 06/30/2026 | 1190294606 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $10,616.04 | 12/17/2025 | Non-covered Recipient Entity ENDEAVOR HEALTH | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190301459 |
| Recipient | Novartis Pharmaceuticals Corporation | $1,954.96 | 12/12/2025 | Covered Recipient Physician | Research Publication/ Writing Support | No dispute reported | 06/30/2026 | 1190293314 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,736.12 | 12/04/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184133347 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,483.37 | 12/04/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184133349 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $31,787.00 | 12/01/2025 | Covered Recipient Teaching Hospital Skokie Hospital | A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U | No dispute reported | 06/30/2026 | 1190298057 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,030.00 | 11/24/2025 | Non-covered Recipient Entity ENDEAVOR HEALTH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192142363 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,000.00 | 11/24/2025 | Non-covered Recipient Entity ENDEAVOR HEALTH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192142383 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,094.44 | 11/21/2025 | Non-covered Recipient Entity ENDEAVOR HEALTH | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192145065 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 11/14/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184133341 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,580.00 | 11/14/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184133343 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 11/14/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184133345 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,438.98 | 10/29/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184133339 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $10,381.14 | 10/23/2025 | Non-covered Recipient Entity ENDEAVOR HEALTH | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192136304 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,483.37 | 10/23/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184133337 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,736.12 | 10/16/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184133335 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $269.76 | 10/08/2025 | Covered Recipient Teaching Hospital Skokie Hospital | A double-blind, randomized, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of remibrutinib (LOU064) for 24 weeks in adolescents from 12 to less than 18 years of age with chronic spontaneous urticaria inadequately controlled | No dispute reported | 06/30/2026 | 1190298061 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $32,146.03 | 10/08/2025 | Covered Recipient Teaching Hospital Skokie Hospital | A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately co | No dispute reported | 06/30/2026 | 1190298065 |
| Recipient | GENZYME CORPORATION | $500.00 | 09/30/2025 | Covered Recipient Physician | A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma | No dispute reported | 06/30/2026 | 1226119002 |
| Recipient | GENZYME CORPORATION | $250.00 | 09/30/2025 | Covered Recipient Physician | A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma | No dispute reported | 06/30/2026 | 1226119010 |
| Recipient | GENZYME CORPORATION | $500.00 | 09/29/2025 | Covered Recipient Physician | A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma | No dispute reported | 06/30/2026 | 1226119020 |
| Recipient | GENZYME CORPORATION | $250.00 | 09/28/2025 | Covered Recipient Physician | A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma | No dispute reported | 06/30/2026 | 1226119006 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,722.98 | 09/23/2025 | Covered Recipient Teaching Hospital Skokie Hospital | A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks | No dispute reported | 06/30/2026 | 1190294599 |
| Principal investigator 1 | Genentech, Inc. | $26,676.00 | 09/18/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | RO IIS 2022 21359 | No dispute reported | 06/30/2026 | 1211551330 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,506.58 | 09/17/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244047265 |
| Principal investigator 1 | GENZYME CORPORATION | $1,875.00 | 09/15/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226140544 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,521.30 | 09/12/2025 | Non-covered Recipient Entity ENDEAVOR HEALTH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192142390 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 09/12/2025 | Non-covered Recipient Entity ENDEAVOR HEALTH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192142416 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $17,642.00 | 09/04/2025 | Non-covered Recipient Entity ENDEAVOR HEALTH | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192136310 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 09/03/2025 | Non-covered Recipient Entity ENDEAVOR HEALTH | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192136298 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $638.44 | 09/01/2025 | Covered Recipient Physician | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184120791 |
| Principal investigator 1 | AstraZeneca UK Limited | $18,275.00 | 08/28/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma | No dispute reported | 06/30/2026 | 1185541690 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $590.00 | 08/21/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244047263 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $15,700.00 | 08/12/2025 | Non-covered Recipient Entity ENDEAVOR HEALTH CLINICAL OPERATIONS - | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | No dispute reported | 06/30/2026 | 1192136279 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 08/12/2025 | Non-covered Recipient Entity ENDEAVOR HEALTH CLINICAL OPERATIONS - | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | No dispute reported | 06/30/2026 | 1192145078 |
| Principal investigator 1 | Genentech, Inc. | $1,100.00 | 08/07/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | RO IIS 2022 21359 | No dispute reported | 06/30/2026 | 1211551357 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 07/30/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133331 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 07/30/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133333 |
| Principal investigator 1 | Genentech, Inc. | $26,676.00 | 07/29/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | RO IIS 2022 21359 | No dispute reported | 06/30/2026 | 1211551343 |
| Principal investigator 1 | Genentech, Inc. | $26,676.00 | 07/29/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | RO IIS 2022 21359 | No dispute reported | 06/30/2026 | 1211551347 |
| Principal investigator 1 | Genentech, Inc. | $26,676.00 | 07/22/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | RO IIS 2022 21359 | No dispute reported | 06/30/2026 | 1211551338 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $7,677.18 | 07/22/2025 | Non-covered Recipient Entity ENDEAVOR HEALTH CLINICAL OPERATIONS - | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | No dispute reported | 06/30/2026 | 1192136289 |
| Principal investigator 1 | ARS Pharmaceuticals Operations, Inc. | $19,850.00 | 07/17/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | FREQUENT URTICARIA FLARES IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA (EPI U02) (THE STUDY) | No dispute reported | 06/30/2026 | 1245870866 |
| Principal investigator 1 | ARS Pharmaceuticals Operations, Inc. | $3,000.00 | 07/17/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | FREQUENT URTICARIA FLARES IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA (EPI U02) (THE STUDY) | No dispute reported | 06/30/2026 | 1245870869 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $84,322.50 | 07/15/2025 | Non-covered Recipient Entity ENDEAVOR HEALTH | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190301461 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,012.58 | 07/10/2025 | Non-covered Recipient Entity ENDEAVOR HEALTH CLINICAL OPERATIONS - | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | No dispute reported | 06/30/2026 | 1192136283 |
| Recipient | GENZYME CORPORATION | $500.00 | 07/09/2025 | Covered Recipient Physician | Registry of Asthma Patients Initiating DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1226119014 |
| Recipient | GENZYME CORPORATION | $250.00 | 07/09/2025 | Covered Recipient Physician | Registry of Asthma Patients Initiating DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1226119018 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 07/02/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133311 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 07/02/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133313 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 07/02/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133315 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 07/02/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133317 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 07/02/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133319 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 07/02/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133321 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,535.00 | 07/02/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184133323 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10,000.00 | 07/02/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184133325 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 07/02/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184133327 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 07/02/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184133329 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $1,447.80 | 07/01/2025 | Covered Recipient Physician | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184120789 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 06/30/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184133307 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 06/25/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133303 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 06/25/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133305 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $700.15 | 06/16/2025 | Non-covered Recipient Entity ENDEAVOR HEALTH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192142402 |
| Recipient | GENZYME CORPORATION | $250.00 | 06/13/2025 | Covered Recipient Physician | Registry of Asthma Patients Initiating DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1226118978 |
| Recipient | GENZYME CORPORATION | $500.00 | 06/13/2025 | Covered Recipient Physician | Registry of Asthma Patients Initiating DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1226118982 |
| Recipient | GENZYME CORPORATION | $250.00 | 06/13/2025 | Covered Recipient Physician | Registry of Asthma Patients Initiating DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1226118986 |
| Recipient | GENZYME CORPORATION | $500.00 | 06/13/2025 | Covered Recipient Physician | Registry of Asthma Patients Initiating DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1226118990 |
| Recipient | GENZYME CORPORATION | $250.00 | 06/13/2025 | Covered Recipient Physician | Registry of Asthma Patients Initiating DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1226118994 |
| Recipient | GENZYME CORPORATION | $500.00 | 06/13/2025 | Covered Recipient Physician | Registry of Asthma Patients Initiating DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1226118998 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $592.50 | 06/01/2025 | Covered Recipient Physician | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184120781 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $1,135.00 | 06/01/2025 | Covered Recipient Physician | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184120783 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $915.26 | 06/01/2025 | Covered Recipient Physician | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184120785 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $1,459.29 | 06/01/2025 | Covered Recipient Physician | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184120787 |
| Recipient | F. Hoffmann-La Roche AG | $1,863.75 | 05/29/2025 | Covered Recipient Physician | A Phase III Trial of Xolair in CIU | No dispute reported | 06/30/2026 | 1211535878 |
| Recipient | F. Hoffmann-La Roche AG | $1,863.75 | 05/29/2025 | Covered Recipient Physician | A Phase III Trial of Xolair in CIU | No dispute reported | 06/30/2026 | 1211535883 |
| Recipient | F. Hoffmann-La Roche AG | $1,491.00 | 05/29/2025 | Covered Recipient Physician | Matched-Adjusted Indirect Comparison Analysis Demonstrating Significantly Better Improvement in Patient-Reported Outcomes for Omalizumab vs Dupilumab at 12 Weeks in Patients With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1211535887 |
| Principal investigator 1 | Genentech, Inc. | $53,352.00 | 05/29/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | RO IIS 2022 21359 | No dispute reported | 06/30/2026 | 1211551334 |
| Principal investigator 1 | Incyte Corporation | $10,477.00 | 05/22/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240486579 |
| Recipient | GENZYME CORPORATION | $250.00 | 05/18/2025 | Covered Recipient Physician | Registry of Asthma Patients Initiating DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1226118974 |
| Recipient | GENZYME CORPORATION | $500.00 | 05/16/2025 | Covered Recipient Physician | Registry of Asthma Patients Initiating DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1226118954 |
| Recipient | GENZYME CORPORATION | $250.00 | 05/14/2025 | Covered Recipient Physician | Registry of Asthma Patients Initiating DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1226118958 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $68.20 | 05/14/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244047271 |
| Recipient | GENZYME CORPORATION | $250.00 | 05/13/2025 | Covered Recipient Physician | Registry of Asthma Patients Initiating DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1226118961 |
| Recipient | GENZYME CORPORATION | $500.00 | 05/13/2025 | Covered Recipient Physician | Registry of Asthma Patients Initiating DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1226118964 |
| Recipient | GENZYME CORPORATION | $500.00 | 05/13/2025 | Covered Recipient Physician | Registry of Asthma Patients Initiating DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1226118969 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,735.05 | 05/05/2025 | Non-covered Recipient Entity ENDEAVOR HEALTH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192142408 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $1,135.00 | 05/01/2025 | Covered Recipient Physician | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184120775 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $1,067.80 | 05/01/2025 | Covered Recipient Physician | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184120777 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $1,067.80 | 05/01/2025 | Covered Recipient Physician | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184120779 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 04/30/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133267 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 04/30/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133269 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 04/30/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133271 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 04/30/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133273 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 04/30/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133275 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 04/30/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133277 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 04/30/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133279 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 04/30/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133281 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 04/30/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133283 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 04/30/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133285 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 04/30/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133287 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 04/30/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133289 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 04/30/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133291 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 04/30/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133293 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 04/30/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133295 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 04/30/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133297 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 04/30/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133299 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,281.62 | 04/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244047261 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $76,620.16 | 04/15/2025 | Non-covered Recipient Entity ENDEAVOR HEALTH | A 12-week randomized, participant and investigator-blinded, placebo-controlled, exploratory study in adult participants with Chronic Urticaria to assess the Efficacy and Safety and explore the Mechanism of Action of remibrutinib (LOU064) | No dispute reported | 06/30/2026 | 1190301463 |
| Principal investigator 1 | Incyte Corporation | $3,250.00 | 04/10/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240486569 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,033.60 | 04/04/2025 | Non-covered Recipient Entity ENDEAVOR HEALTH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192142371 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $309.38 | 04/01/2025 | Covered Recipient Physician | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184120767 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $416.67 | 04/01/2025 | Covered Recipient Physician | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184120769 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $60.00 | 04/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184120771 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $416.67 | 04/01/2025 | Covered Recipient Physician | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184120773 |
| Recipient | Novartis Pharma AG | $4,337.00 | 03/20/2025 | Covered Recipient Physician | CLOU064A2301,CLOU064A2302 | No dispute reported | 06/30/2026 | 1248109281 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,134.90 | 03/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244047259 |
| Principal investigator 1 | Genentech, Inc. | $26,676.00 | 03/15/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | RO IIS 2022 21359 | No dispute reported | 06/30/2026 | 1211551351 |
| Principal investigator 1 | Genentech, Inc. | $3,300.00 | 03/15/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | RO IIS 2022 21359 | No dispute reported | 06/30/2026 | 1211551355 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $841.00 | 03/07/2025 | Non-covered Recipient Entity ENDEAVOR HEALTH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192136316 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $737.00 | 03/07/2025 | Non-covered Recipient Entity ENDEAVOR HEALTH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192136328 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,226.00 | 03/07/2025 | Non-covered Recipient Entity ENDEAVOR HEALTH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192142396 |
| Recipient | Novartis Pharmaceuticals Corporation | $4,602.13 | 03/02/2025 | Covered Recipient Physician | CLOU064A2201,CLOU064A2301,CLOU064A2302 | No dispute reported | 06/30/2026 | 1190292406 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,126.52 | 02/27/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244047257 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $204.60 | 02/21/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244047269 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $28,914.58 | 02/13/2025 | Non-covered Recipient Entity NORTHSHORE UNIVERSITY HEALTH SYSTEM NORTHSHORE UNIVERSITY HEALTH SYSTEM RESEARCH INSTITUTE | A double-blind, randomized, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of remibrutinib (LOU064) for 24 weeks in adolescents from 12 to less than 18 years of age with chronic spontaneous urticaria inadequately controlled | No dispute reported | 06/30/2026 | 1190300579 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,522.00 | 02/07/2025 | Non-covered Recipient Entity ENDEAVOR HEALTH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192136321 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 02/03/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133253 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 02/03/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133255 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 02/03/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133257 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $489.11 | 02/03/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133259 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $353.57 | 02/01/2025 | Covered Recipient Physician | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184120755 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $353.57 | 02/01/2025 | Covered Recipient Physician | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184120757 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $416.67 | 02/01/2025 | Covered Recipient Physician | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184120759 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $353.57 | 02/01/2025 | Covered Recipient Physician | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184120761 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $353.57 | 02/01/2025 | Covered Recipient Physician | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184120763 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $416.67 | 02/01/2025 | Covered Recipient Physician | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184120765 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $52,699.63 | 01/30/2025 | Non-covered Recipient Entity NORTHSHORE UNIVERSITY HEALTH SYSTEM NORTHSHORE UNIVERSITY HEALTH SYSTEM RESEARCH INSTITUTE | A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately co | No dispute reported | 06/30/2026 | 1190300583 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $12,500.02 | 01/28/2025 | Non-covered Recipient Entity NORTHSHORE UNIVERSITY HEALTH SYSTEM NORTHSHORE UNIVERSITY HEALTH SYSTEM RESEARCH INSTITUTE | A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U | No dispute reported | 06/30/2026 | 1190300577 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,966.70 | 01/16/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244047255 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,679.60 | 01/13/2025 | Non-covered Recipient Entity ENDEAVOR HEALTH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192142376 |
| Principal investigator 1 | Incyte Corporation | $6.60 | 01/09/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240486471 |
| Principal investigator 1 | Incyte Corporation | $60.58 | 01/09/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240486476 |
| Principal investigator 1 | Incyte Corporation | $32.32 | 01/09/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240486481 |
| Principal investigator 1 | Incyte Corporation | $9.18 | 01/09/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240486487 |
| Principal investigator 1 | Incyte Corporation | $6.00 | 01/09/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240486494 |
| Principal investigator 1 | Incyte Corporation | $4.32 | 01/09/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240486500 |
| Principal investigator 1 | Incyte Corporation | $9.32 | 01/09/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240486506 |
| Principal investigator 1 | Incyte Corporation | $52.48 | 01/09/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240486511 |
| Principal investigator 1 | Incyte Corporation | $74.64 | 01/09/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240486517 |
| Principal investigator 1 | Incyte Corporation | $205.26 | 01/09/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240486522 |
| Principal investigator 1 | Incyte Corporation | $5.40 | 01/09/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240486528 |
| Principal investigator 1 | Incyte Corporation | $4.66 | 01/09/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240486533 |
| Principal investigator 1 | Incyte Corporation | $4.66 | 01/09/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240486538 |
| Principal investigator 1 | Incyte Corporation | $1.20 | 01/09/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240486544 |
| Principal investigator 1 | Incyte Corporation | $16.16 | 01/09/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240486552 |
| Principal investigator 1 | Incyte Corporation | $8.64 | 01/09/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240486558 |
| Principal investigator 1 | Incyte Corporation | $9.32 | 01/09/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240486565 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133014 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133016 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $89.10 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133018 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.64 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133020 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133022 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133024 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133026 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26.40 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133028 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $66.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133030 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133032 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26.40 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133034 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $89.10 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133036 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.64 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133038 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133040 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133042 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133044 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133046 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133048 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133050 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $66.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133052 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133054 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26.40 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133056 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $89.10 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133058 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26.40 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133060 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $66.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133062 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133064 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26.40 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133066 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $89.10 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133068 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133070 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $66.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133072 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133074 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26.40 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133076 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $89.10 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133078 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133080 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26.40 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133082 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26.40 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133084 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26.40 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133086 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $89.10 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133088 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133090 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $66.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133092 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $66.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133094 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133096 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26.40 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133098 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26.40 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133100 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $89.10 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133102 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133104 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $66.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133106 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133108 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26.40 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133110 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $89.10 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133112 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133114 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $66.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133116 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133118 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26.40 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133120 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $89.10 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133122 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133124 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133126 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133128 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $66.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133130 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133132 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $50.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133134 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $66.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133136 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133138 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133140 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26.40 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133142 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $89.10 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133144 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133146 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $89.10 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133148 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133150 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $66.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133152 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133154 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26.40 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133156 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $89.10 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133158 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133160 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133162 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133164 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26.40 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133166 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $66.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133168 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133170 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $89.10 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133172 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26.40 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133174 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133176 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $66.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133178 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133180 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133182 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133184 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.64 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133186 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $89.10 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133188 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26.40 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133190 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133192 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $66.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133194 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133196 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26.40 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133198 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $89.10 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133200 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133202 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133204 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $66.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133206 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26.40 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133208 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26.40 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133210 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $89.10 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133212 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133214 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $66.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133216 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133219 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26.40 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133221 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $89.10 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133223 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133225 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133227 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133229 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26.40 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133231 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $66.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133233 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133235 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26.40 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133237 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $89.10 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133239 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133241 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133243 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133245 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26.40 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133247 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $66.00 | 01/08/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184133249 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $43,207.89 | 01/01/2025 | Covered Recipient Teaching Hospital Skokie Hospital | A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U | No dispute reported | 06/30/2026 | 1190294595 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $75,725.26 | 01/01/2025 | Covered Recipient Teaching Hospital Skokie Hospital | A double-blind, randomized, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of remibrutinib (LOU064) for 24 weeks in adolescents from 12 to less than 18 years of age with chronic spontaneous urticaria inadequately controlled | No dispute reported | 06/30/2026 | 1190294602 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $37,753.42 | 01/01/2025 | Covered Recipient Teaching Hospital Skokie Hospital | A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately co | No dispute reported | 06/30/2026 | 1190294609 |